Glenmark Pharmaceuticals Limited or GLENMARK

Glenmark Pharmaceuticals was being incorporated in 1977, and then it entered into the dermatology market by 1979 via the launch of its Candid Cream. Soon it became a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with the help of eight molecules in various stages of the clinical development. It also operates in the formulation business in over 95 countries, which also includes India. It has a significant presence in branded generics markets across emerging economies, including India. And its subsidiary, named Glenmark Generics Limited has a fast growing and robust US generics business. It also markets APIs to regulated & semi-regulated countries and employs nearly 6000 people in over 80 countries worldwide. It has approximately twelve manufacturing facilities in over four countries and also has five R&D centers. The Glenmark was also chosen as one of the "Best Pharma Company in the World – SME" and "Best Company across emerging markets" for 2008 by SCRIP, it is also the most significant selling as well as the most respected pharmaceutical magazine in the world. And then Forbes, which is another leading international publication, recognized Glenmark as the "Best under a Billion Dollar companies in Asia" for 2008. The vision of this company is to emerge as a leading integrated research-based, global pharmaceutical company and over the decades, it has established itself as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) as well as NBEs (New Biological Entity). Now, they have several molecules in various stages of the preclinical and clinical development, and it is also primarily focused in the areas of Oncology, Respiratory & Dermatology. The generics business services the requirements of the developed markets like US & Western Europe and API business sells its products in approximately 80 countries worldwide which includes the US, and various other countries in the EU, and South America and India. And with the 17 manufacturing facilities and 5 R&D centers which are dedicated to the goal of enriching lives across the world and they believe that the real force behind their continued successes is the dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world.'

Here are some of the Business area of the company

1. Specialty Business: Drug Discovery:

The breaking drug discovery effort is the prime focus in the areas of inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, and much more.] And pain [neuropathic pain and inflammatory pain]. It also has a robust pipeline which includes 13 molecules in various stages of preclinical & clinical development. And out of these, eight molecules are in clinical trials. Such types of molecules in clinical development are mainly used to focus on advanced treatments for chronic/debilitating diseases, and they are potential blockbusters with potential peak sales opportunity for each molecule being within the range of $1 billion to $3 billion.

2. Specialty Business: Formulations Business:

This business is currently organized around four major regions, which are India, Latin America, and Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. This business focuses on therapeutic areas such as dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and lastly oncology. Also, India has become one of the largest markets in terms of revenue source for the organization. It has five manufacturing facilities; in which three in India and the other two are overseas. Several regulatory bodies are approving all such facilities.

The Milestones:

1. 2010:

The Glenmark Pharmaceuticals Ltd has entered into a settlement and the license agreement with Sepracor Incorporation to market generic Eszopiclone tablets.

2. 2011:

• Glenmark wins Two Prestigious Global Recognitions at SCRIP Awards 2011.
• Glenmark forays into Cosmeceutical Segment.

3. 2012:

Forest Laboratories and Glenmark Sign Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions."